Skip to main content
Cipher Pharmaceuticals Inc. logo

Cipher Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · CPHRF ISIN · CA17253X1050 LEI · 213800T44AN9XSAOY605 TSX Manufacturing
Open in API
Filings indexed 165 across all filing types
Latest filing 2026-04-16 Proxy Solicitation & In…
Country CA Canada
Listing TSX CPHRF

About Cipher Pharmaceuticals Inc.

https://www.cipherpharma.com/

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, marketing, and managing a diversified portfolio of commercial and pipeline products, primarily within the dermatology sector. The company seeks to fulfill unmet medical needs by acquiring best-in-class products and managing the necessary clinical development and regulatory processes. Its portfolio includes key commercial products such as Epuris (isotretinoin), an oral retinoid indicated for the treatment of acne. Cipher's strategy involves continually evaluating businesses with commercial products for merger or acquisition opportunities to expand its offerings.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal “Notice of Meeting” filed to Canadian Securities Regulators, detailing the Annual General and Special Meeting dates, record dates, and proxy delivery arrangements. It pertains to the proxy solicitation process and provides meeting and voting details to shareholders (and regulators) ahead of the AGM. This aligns with “Proxy Solicitation & Information Statement” filings (PSI).
2026-04-16 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice to regulators detailing the date, record dates, and logistical particulars for the upcoming Annual General and Special Meeting of security holders. It is not the actual AGM presentation or materials, nor is it a results declaration. It clearly falls under “Materials sent to shareholders to provide information and request votes for meetings,” which corresponds to Proxy Solicitation & Information Statement (PSI).
2026-04-16 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F1 management certification under Canadian NI 52-109 attesting to review of annual filings (AIF, financial statements, MD&A) and controls. It is not the Annual Report itself, nor an auditor’s report, earnings release, proxy statement, or presentation. It is a regulatory filing required by securities legislation, fitting the fallback category “Regulatory Filings” (RNS).
2026-03-30 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F1 certification by the CFO under Canadian National Instrument 52-109, certifying the issuer’s annual filings. It is neither the annual MD&A nor financial statements themselves, nor an announcement of a dividend or vote, nor a press release. It is a regulatory compliance certificate falling outside specific categories such as 10-K, IR, ER etc. Therefore it best fits the fallback Regulatory Filings category (RNS).
2026-03-30 English
Annual information form - English.pdf
Annual Report Classification · 1% confidence The document is titled '2025 Annual Information Form' for Cipher Pharmaceuticals Inc. An Annual Information Form (AIF) is a specific regulatory disclosure document required by Canadian securities regulators that provides material information about a company, its business, and its risks. While it is not a 10-K (which is a US-specific filing), it serves the same functional purpose as a comprehensive annual disclosure document. Given the provided categories, '10-K' is the closest functional equivalent for a comprehensive annual regulatory disclosure document, though it is technically an AIF. FY 2025
2026-03-30 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release from Cipher Pharmaceuticals announcing that Health Canada has accepted their New Drug Submission (NDS) for review. This is a corporate announcement regarding regulatory progress for a specific product, which does not fit into financial reporting categories like 10-K or IR, nor does it announce a report publication. As it is a general regulatory/corporate announcement, it falls under the RNS (Regulatory Filings) category.
2026-01-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.